EDSA
Edesa Biotech, Inc.
Key Financials
Operating Income
$-7911566
↓ 12.8%
Net Income
$-7185523
↓ 16.5%
EPS (Diluted)
$-0.57
↓ 58.3%
Shareholders' Equity
$12.5M
↑ 528.5%
Total Assets
$13.5M
↑ 254.8%
Revenue
$0
↓ 100.0%
Total Liabilities
$1.8M
↓ 0.5%
Cash & Equivalents
$10.8M
↑ 980.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 4/10/2026 | View on SEC |
| ARS | 4/3/2026 | View on SEC |
| DEFA14A | 4/3/2026 | View on SEC |
| DEF 14A | 4/3/2026 | View on SEC |
| SCHEDULE 13G | 3/16/2026 | View on SEC |
| 4 | 3/11/2026 | View on SEC |
| 4 | 3/10/2026 | View on SEC |
| 4 | 3/6/2026 | View on SEC |
| 4 | 3/5/2026 | View on SEC |
| 4 | 3/4/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | EDSA |
| Company Name | Edesa Biotech, Inc. |
| CIK | 1540159 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 0930 |
| State of Incorporation | A1 |
| Phone | (905) 475-1234 |